Logo image of HCM

HUTCHMED CHINA-ADR (HCM) Stock Price, Forecast & Analysis

USA - NASDAQ:HCM - US44842L1035 - ADR

14.65 USD
+0.22 (+1.52%)
Last: 10/31/2025, 12:09:46 PM

HCM Key Statistics, Chart & Performance

Key Statistics
Market Cap2.52B
Revenue(TTM)602.20M
Net Income(TTM)466.88M
Shares171.87M
Float99.11M
52 Week High19.5
52 Week Low11.51
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)2.72
PE5.39
Fwd PE30.88
Earnings (Next)03-17 2026-03-17/amc
IPO2006-05-19
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


HCM short term performance overview.The bars show the price performance of HCM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

HCM long term performance overview.The bars show the price performance of HCM in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 60

The current stock price of HCM is 14.65 USD. In the past month the price decreased by -10.48%. In the past year, price decreased by -22.54%.

HUTCHMED CHINA-ADR / HCM Daily stock chart

HCM Latest News, Press Relases and Analysis

HCM Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 38.97 811.03B
JNJ JOHNSON & JOHNSON 18.16 454.02B
AZN ASTRAZENECA PLC-SPONS ADR 18.41 253.48B
NVS NOVARTIS AG-SPONSORED ADR 13.79 238.87B
NVO NOVO-NORDISK A/S-SPONS ADR 12.65 216.99B
MRK MERCK & CO. INC. 9.79 213.04B
PFE PFIZER INC 7.25 139.72B
SNY SANOFI-ADR 11.53 123.36B
GSK GSK PLC-SPON ADR 7.76 94.60B
BMY BRISTOL-MYERS SQUIBB CO 7.06 94.29B
ZTS ZOETIS INC 23.12 63.73B
TAK TAKEDA PHARMACEUTIC-SP ADR 48.11 42.54B

About HCM

Company Profile

HCM logo image HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Company Info

HUTCHMED CHINA-ADR

48th Floor, Cheung Kong Center, 2 Queen's Road Central

Hong Kong HK

CEO: Christian Hogg

Employees: 1780

HCM Company Website

HCM Investor Relations

Phone: 85221281188

HUTCHMED CHINA-ADR / HCM FAQ

Can you describe the business of HUTCHMED CHINA-ADR?

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.


What is the stock price of HUTCHMED CHINA-ADR today?

The current stock price of HCM is 14.65 USD. The price increased by 1.52% in the last trading session.


What is the dividend status of HUTCHMED CHINA-ADR?

HCM does not pay a dividend.


How is the ChartMill rating for HUTCHMED CHINA-ADR?

HCM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


On which exchange is HCM stock listed?

HCM stock is listed on the Nasdaq exchange.


What is the expected growth for HCM stock?

The Revenue of HUTCHMED CHINA-ADR (HCM) is expected to decline by -11.78% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the outstanding short interest for HUTCHMED CHINA-ADR?

The outstanding short interest for HUTCHMED CHINA-ADR (HCM) is 0.37% of its float.


HCM Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HCM Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to HCM. HCM has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HCM Financial Highlights

Over the last trailing twelve months HCM reported a non-GAAP Earnings per Share(EPS) of 2.72. The EPS increased by 1172.34% compared to the year before.


Industry RankSector Rank
PM (TTM) 77.53%
ROA 26.29%
ROE 37.99%
Debt/Equity 0.08
Chartmill High Growth Momentum
EPS Q2Q%1661.49%
Sales Q2Q%-9.16%
EPS 1Y (TTM)1172.34%
Revenue 1Y (TTM)-1.41%

HCM Forecast & Estimates

27 analysts have analysed HCM and the average price target is 17.05 USD. This implies a price increase of 16.36% is expected in the next year compared to the current price of 14.65.

For the next year, analysts expect an EPS growth of 897.09% and a revenue growth -11.78% for HCM


Analysts
Analysts83.7
Price Target17.05 (16.38%)
EPS Next Y897.09%
Revenue Next Year-11.78%

HCM Ownership

Ownership
Inst Owners21.97%
Ins Owners0.58%
Short Float %0.37%
Short Ratio7.31